AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11518436
Drug: Instrumental Enrichment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Instrumental Enrichment (dynamic cognitive treatment)
Trial: 11518436
Drug: Traditional occupational
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional occupational therapy methods (control group)
Trial: 9844792
Drug: Morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (10 mg/70 kg bolus and 3.5 mg/70 kg/hour for 4 hours)
Trial: 9844792
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and M-6-G combination
Trial: 9844792
Drug: M-6-G (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-6-G (doses producing plasma concentrations identical, 2x, or 3x higher than morphine)
Trial: 8822914
Drug: Hydroxyurea (HU)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (HU) at an initial dosage of 20 mg/kg/d for 6 months
Trial: 2184135
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus poly(A).poly(U)
Trial: 6788319
Drug: Diazepam (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (25 mg daily)
Trial: 6788319
Drug: Promethazine (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine (125 mg daily)
Trial: 30556414
Drug: Desoximetasone 0.25%
RxNorm normalized name: DESOXIMETASONE 0.25% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desoximetasone 0.25% spray plus twice‐daily phone call reminders
Trial: 27852718
Drug: High-intensity interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity interval training (HIIT) consisting of 10 high-intensity (85-90% peak power output) and 10 low-intensity (20-25% peak power output) intervals, each lasting 1 minute, for 8 weeks, twice weekly.
Trial: 27852718
Drug: Moderate-intensity steady-state
RxNorm normalized name: CLOZAPINE (GOLDEN STATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity steady-state training (MISS) following usual care recommendations, adhering to UK guidelines (>20 minutes continuous exercise at 40-70% heart rate reserve), for 8 weeks, twice weekly.
Trial: 20424418
Drug: 0.7 mg/m2/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 mg/m2/day biosynthetic GH
Trial: 20424418
Drug: 1.4 mg/m2/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m2/day biosynthetic GH
Trial: 15730354
Drug: Various medications
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various medications (specific medications not detailed)
Trial: 9043535
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) 7 mg over 8 hours via metered-dose inhaler (MDI) attached to a holding chamber
Trial: 9043535
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered in the same fashion as BDP
Trial: 2438966
Drug: Antihistamine/decongestant
RxNorm normalized name: ANTIHISTAMINE/DECONGESTANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine/decongestant
Trial: 29787355
Drug: Lavender cream
RxNorm normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lavender cream and footbath
Trial: 29787355
Drug: Lavender cream
RxNorm normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lavender cream alone
Trial: 20335158
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) and azithromycin (10 mg/kg daily, intravenously)
Trial: 20335158
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg daily, intravenously)
Trial: 20335158
Drug: Combined treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatments (TCM and WM)
Trial: 15780168
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose rate brachytherapy monotherapy
Trial: 15780168
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy options
Trial: 15780168
Drug: Matched analyses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched analyses with uniform patient treatment and pathological review
Trial: 16245220
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (10 mg/kg/day)
Trial: 1888818
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg famotidine nocte
Trial: 1888818
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine nocte
Trial: 30080254
Drug: Intravenous alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alcohol self-administration after 2 weeks of abstinence
Trial: 27997653
Drug: Pritelivir 100
RxNorm normalized name: Pritelivir
DrugBank: Pritelivir (DB11844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pritelivir 100 mg daily for 28 days
Trial: 27997653
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg daily for 28 days
Trial: 24488184
Drug: Direct-to-consumer advertising
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-to-consumer advertising (DTCA) about Cymbalta (an antidepressant)
Trial: 22281110
Drug: PPI and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI and rebamipide combination therapy
Trial: 16390780
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement (2 mg estradiol/day, orally for 90 days)
Trial: 11940322
Drug: Intravenous rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous rt-PA therapy plus rescue intracoronary stenting
Trial: 9804012
Drug: Dynamic CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic CT with intravenous administration of 40 ml Ioversol (5 cc/s)
Trial: 8904479
Drug: Indomethacin treatment
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin treatment for 'silent' PDA
Trial: 203832
Drug: Clofibrate and
RxNorm normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofibrate and m-Inositolnicotinate (1.5 g Clofibrate and 1.2 g m-Inositolnicotinate daily)
Trial: 203832
Drug: Clofibrate or
RxNorm normalized name: clofibrate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibrate or clofibrinic acid (monotherapy)
Trial: 203832
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Clofibrate with m-Inositolnicotinate)
Trial: 203832
Drug: Pure nicotinic
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pure nicotinic acid (3 to 4 g/daily) or its esters (4 to 6 g/daily) or beta-Pyridylcarbinol (800 to 1200 mg/daily)
Trial: 203832
Drug: Increased dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dosage of nicotinic acid
Trial: 26216919
Drug: Choice-based reality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choice-based reality therapy
Trial: 25880805
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg od
Trial: 23674107
Drug: Nebulized isotonic
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized isotonic saline (3 mL)
Trial: 23674107
Drug: Nebulized water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized water (3 mL)
Trial: 19695391
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg orally dispersible tablet
Trial: 19695391
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg orally dispersible tablet
Trial: 19695391
Drug: Reference 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference 100 mg capsule
Trial: 17041858
Drug: 16-week structured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-week structured treatment interruption (STI) followed by optimized ART
Trial: 10654902
Drug: Low-dose estrogen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose estrogen patch (0.05 mg applied twice weekly for 4 weeks)
Trial: 10654902
Drug: High-dose estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose estrogen patch (0.10 mg applied twice weekly for 4 weeks)
Trial: 8375373
Drug: 0.2 g
RxNorm normalized name: methionine 0.2 gram ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g lecithin.kg body mass-1 before exercise
Trial: 8375373
Drug: 0.2 g
RxNorm normalized name: methionine 0.2 gram ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g lecithin.kg body mass-1 without exercise
Trial: 3093237
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg lithium carbonate daily for 3 weeks
Trial: 3093237
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (3 nights during therapy)
Trial: 3093237
Drug: Post-treatment (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-treatment (2 registrations after lithium carbonate was discontinued)
Trial: 24814890
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (three doses)
Trial: 18801404
Drug: Buprenorphine (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (highest dose 32 mg/day)
Trial: 18801404
Drug: Methadone (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (highest dose 200 mg/day)
Trial: 15739214
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (LAS, TS, and nifedipine)
Trial: 14716878
Drug: 131I-HAb18F(ab')2 injected
RxNorm normalized name: iobenguane (131I)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 131I-HAb18F(ab')2 injected into the target hepatic artery at doses of 0.5, 0.75, 1.0 mCi/kg
Trial: 10362732
Drug: L-NMMA (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (4 mg. kg-1. h-1)
Trial: 10362732
Drug: L-NAME (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME (75 or 180 micrograms . kg-1. h-1)
Trial: 27411361
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) with AV delay optimization
Trial: 27411361
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) with reduced LV activation time
Trial: 24255104
Drug: Salsalate 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salsalate 3.5 g/day for 48 weeks
Trial: 22971188
Drug: High UVA-protection
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High UVA-protection sunscreen applied at 2 mg/cm²
Trial: 22971188
Drug: Low UVA-protection
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low UVA-protection sunscreen applied at 2 mg/cm²
Trial: 22971188
Drug: High UVA-protection
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High UVA-protection sunscreen applied at 1 mg/cm²
Trial: 22971188
Drug: Low UVA-protection
RxNorm normalized name: UVA URSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low UVA-protection sunscreen applied at 1 mg/cm²
Trial: 19200365
Drug: RCT (50.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCT (50.4 Gy in 28 fractions of 1.8 Gy, continuous infusion 5-fluorouracil) plus TME-surgery 4-6 weeks later
Trial: 19200365
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups receive adjuvant chemotherapy (12 weeks continuous infusional 5-FU)
Trial: 17095923
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3) ingestion (0.3 g x kg(‐1) body mass in 1 L of fluid)
Trial: 11354392
Drug: Clarithromycin MR
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin MR 500 mg once daily
Trial: 11354392
Drug: Clarithromycin IR
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin IR 250 mg twice daily
Trial: 3155334
Drug: Dentine adhesives
RxNorm normalized name: dendropanax dentiger root with stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentine adhesives and composites used in combination
Trial: 31852207
Drug: Sevoflurane +
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane + high-dose remifentanil (SH)
Trial: 31852207
Drug: Sevoflurane +
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane + low-dose remifentanil (SL)
Trial: 31852207
Drug: Propofol +
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol + high-dose remifentanil (PH)
Trial: 31076468
Drug: ICH-1 formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICH-1 formula (12.1% treatment-emergent adverse events)
Trial: 31076468
Drug: Placebo (5.8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5.8% treatment-emergent adverse events)
Trial: 31076468
Drug: ICH-2 formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICH-2 formula (2.8% treatment-emergent adverse events)
Trial: 28266765
Drug: OCV-C02 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCV-C02 (0.3 mg/body)
Trial: 28266765
Drug: OCV-C02 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCV-C02 (1 mg/body)
Trial: 28266765
Drug: OCV-C02 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCV-C02 (3 mg/body)
Trial: 28266765
Drug: OCV-C02 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCV-C02 (6 mg/body)
Trial: 28266765
Drug: OCV-C02 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCV-C02 (0.3 to 6 mg/body)
Trial: 14678271
Drug: Nicotinamide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (4 g orally, total dose of 8 g)
Trial: 11936571
Drug: Modafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (200 mg on Days 1-7; 400 mg on Days 8-28) + Dextroamphetamine (20 mg on Days 22-28)
Trial: 11936571
Drug: Modafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (200 mg on Days 1-7; 400 mg on Days 8-28)
Trial: 11928147
Drug: IMZ implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMZ implant
Trial: 11928147
Drug: Clinical Implant
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical Implant Performance scale (CIP)
Trial: 7774069
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CSA) at doses <5 mg/kg/day
Trial: 5077919
Drug: Spontaneous reporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spontaneous reporting of adverse reactions to drugs
Trial: 27712461
Drug: Cyanoacrylate treatment
RxNorm normalized name: ethyl cyanoacrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyanoacrylate treatment (n = 218 teeth)
Trial: 27712461
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment (n = 216 teeth)
Trial: 25791540
Drug: Intramuscular olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular olanzapine (10 mg)
Trial: 25791540
Drug: Intramuscular haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular haloperidol (5 mg) plus lorazepam (2 mg)
Trial: 23335971
Drug: Hyperbaric Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric Oxygen Therapy (HBOT) - 40 sessions over 2 months, 5 days/week, 90 minutes each, 100% oxygen at 2 ATA
Trial: 23335971
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (cross group) - no treatment for 2 months followed by 40 HBOT sessions
Trial: 16940980
Drug: CPT-11 (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11 (90 mg/m(2) three times weekly) concomitant to hyperfractionated accelerated radiotherapy (HART)
Trial: 9129484
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of uncooked cornstarch (UCS; 1.76 +/- 0.41 g/kg) at 2100
Trial: 9129484
Drug: Divided doses
RxNorm normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided doses of uncooked cornstarch (UCS; 1.76 +/- 0.41 g/kg) at 2100 and 0200
Trial: 7964948
Drug: Prophylactic cranial
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic cranial irradiation (PCI) at a dosage of 30 to 38 Gy in 2- to 3.6-Gy fractions
Trial: 3581696
Drug: Cytotoxic drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic drug treatment (T-group)
Trial: 3581696
Drug: Symptomatic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic drugs only (NT-group)
Trial: 23238223
Drug: modified constraint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified constraint induced movement therapy (mCIMT)
Trial: 16611388
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg policosanol daily for 12 weeks
Trial: 27101581
Drug: IV Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Methotrexate (MTX), 0.4 mg/kg daily for 5 days every 14 days (25 mg maximum daily dose)
Trial: 27101581
Drug: IV Actinomycin-D
RxNorm normalized name: ACTINOMYCIN-D
DrugBank: Dactinomycin (DB00970)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Actinomycin-D (Act-D), 1.25 mg/m (2 mg maximum dose) every 14 days
Trial: 15676045
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (1 mg Bupi and 0.1 mg HA)
Trial: 15676045
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (0.5 mg Bupi and 0.1 mg HA)
Trial: 15676045
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C (1 mg Bupi and 0 mg HA)
Trial: 12324672
Drug: BEC‐HFA 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEC‐HFA 500 micro g/day
Trial: 12324672
Drug: BEC‐HFA 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEC‐HFA 1000 micro g/day
Trial: 12324672
Drug: FLU‐HFA 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLU‐HFA 500 micro g/day
Trial: 12324672
Drug: FLU‐HFA 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLU‐HFA 1000 micro g/day
Trial: 11776508
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of GnRH antagonist (Cetrotide)
Trial: 11776508
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of GnRH antagonist (Cetrotide)
Trial: 9438891
Drug: i.v. ondansetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ondansetron 0.05 mg/kg
Trial: 9438891
Drug: i.v. ondansetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ondansetron 0.1 mg/kg
Trial: 9438891
Drug: i.v. ondansetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ondansetron 0.15 mg/kg
Trial: 9438891
Drug: oral metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral metoclopramide 0.15 mg/kg + i.v. ondansetron 0.05 mg/kg
Trial: 9438891
Drug: oral metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral metoclopramide 0.15 mg/kg + i.v. ondansetron 0.1 mg/kg
Trial: 9438891
Drug: oral metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral metoclopramide 0.15 mg/kg + i.v. ondansetron 0.15 mg/kg